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guidelines recommendations and positive effect of ACE inhibitors on hypertension
control, the use of ACE inhibitors in hypertensive patients suffering from diabetes
mellitus was suboptimal at Penang Hospital.
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OBJECTIVES: Diabetes increases cardiovascular (CV)/renal risk and thus also in-
creases the importance of optimal control of blood pressure (BP), which is generally
poor among hypertensive patients with diabetes. Poor adherence to antihyperten-
sives is common. Electronic monitoring has shown that treatment lapses among
hypertensives frequently exceed the duration of action of most antihypertensives,
allowing the BP to rise, and reducing these drugs’ real-world effectiveness by in-
creasing CV risk. Use of long-acting antihypertensives may improve BP control
among subjects who, like most, miss doses occasionally. Aliskiren, a direct renin
inhibitor, has been shown in the general hypertensive population to suppress BP
well beyond its 24-hour dosing interval. Its BP-lowering effect is almost uninflu-
enced by a single missed dose, and remains strong after treatment interruptions of
a week (longer than almost all dosing errors). This study examines the duration of
action of aliskiren among hypertensive patients with diabetes. METHODS: BP data
from one to 28 days post-withdrawal, from diabetic subjects in six clinical trials,
were modeled to estimate the extent to which use of aliskiren will ameliorate the
effects of imperfect adherence among diabetic subjects, compared to other
antihypertensives. RESULTS: Thirty-four diabetic subjects had their BP measured
24 hours after treatment withdrawal (48 hours after the last dose). The mean (95%
CI) increase in systolic BP from pre-withdrawal baseline was 0.8 (-3.1 to 4.7)
mmHg. Seventy-three diabetic subjects had their BP measured either six or seven
days after withdrawal. The mean (95% CI) increase in systolic BP from the pre-
withdrawal baseline was 3.4 (0.8 to 6.1) mmHg. CONCLUSIONS:Among diabetics,
as in the general hypertensive population, aliskiren retains much of its effect for a
week after stopping treatment. Its duration of action in diabetic subjects covers the
majority of dosing errors. This may confer advantages over other treatments.
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OBJECTIVES: The objective was to evaluate the clinical efficacy of bisoprolol com-
pared to atenolol in reducing the in-clinic and ambulatory blood pressure in pa-
tients with mild to moderate hypertension.METHODS: Studies were retrieved from
Embase, Pubmed, and Cochrane databases using relevant search strategies. Ran-
domised controlled trials which compared bisoprolol with atenolol were included
according to pre-specified inclusion/exclusion criteria. The outcomes of interest
were reduction in in-clinic systolic/diastolic blood pressure, 24-hour ambulatory
BP (ABP), and reduction in heart rate. Two reviewers independently extracted data
from the included studies. Data was meta-analysed using RevMan (v5). RESULTS:
Of the 1056 studies identified, 11 studies met the inclusion criteria. In total, 624
patients were randomised to bisoprolol, and 683 were randomised to atenolol.
Seven of the included studies were double-blind, three were single-blind and one
was open-label study. The Jadad score of eight studies was 3 and were of high
quality. The study duration of included studies ranged from 8-weeks to 52-weeks.
Results of meta-analysis showed a significantly better reduction of clinical systolic
BP with bisoprolol compared to atenolol (WMD: 3.07 (1.79, 4.35, p0.00001). The
reduction in clinical diastolic BP was significantly better with bisoprolol compared
to atenolol (2.68 (1.88, 3.48, p0.00001). The systolic ABP was significantly reduced
with bisoprolol compared to atenolol (p0.001). The reduction in diastolic ABP was
more with bisoprolol but was not significantly better. A significantly better reduc-
tion in heart rate was achieved with bisoprolol compared to atenolol (1.81 (0.97,
2.65, p0.0001).CONCLUSIONS:This review has included the evidence to date with
regards to reduction of clinical and ambulatory blood pressure with bisoprolol
compared to atenolol. This review concludes that bisoprolol is significantly better
than atenolol in effectively reducing the in-clinic BP, ambulatory BP and heart rate
in patients with mild to moderate essential hypertension.
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OBJECTIVES: To examine the geographic variation trends in the annual prevalence
of critical limb ischemia (CLI) in the US elderly population. METHODS: Using na-
tional medical claims data from 2006 through 2008, all patients who were aged 65
years or older and diagnosed with CLI were identified. The direct standardization
method was used to assess year, age, gender, race and diabetes-adjusted preva-
lence of CLI. The change in prevalence of CLI over the 3 years was assessed and the
variation in the prevalence of CLI was tested by state. RESULTS: Geographic vari-
ation in the prevalence of CLI was obtained for patients over the age of 65 when
adjusted by age, gender, race and diabetes status. Although approximately con-
stant prevalence of CLI was reported in Utah (less than 0.15%) and Maryland
(greater than 0.30%), a progressively increasing prevalence of CLI was observed in
Montana (2006: 0.149%; 2007: 0.163.%; 2008: 0.277%) and Delaware (2006: 0.245%;
2007:0.247%; 2008: 0.330%) while progressively decreasing prevalence of CLI was
observed in Arkansas, Colorado, Georgia, Ohio, Virginia, West Virginia, and Wash-
ington. The total trend over 3 years followed the pattern of higher rates in eastern
states and lower rates in western states. CONCLUSIONS: The spatial distribution of
CLI prevalence is uneven and strongly suggests a geographic variation of CLI risk
areas. Targeted prevention and treatment could help gain better control of CLI in
the United States.
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OBJECTIVES: To use a novel linkage database to describe prescribing patterns in
patients discharged from hospital with acute coronary syndrome (ACS) over a pe-
riod of changing national guidelines. METHODS: Unique identifiers were used to
link patients in a hospital registry (Myocardial Ischaemia National Audit Project),
with longitudinal primary care data (General Practice Research Database). This
retrospective observational study examined post-discharge prescribing patterns
for unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) and ST
elevation MI (STEMI). The population comprised patients 40 years, hospitalised
for ACS from 2003-2009, discharged home, with 3 months follow-up. Patients
were followed from discharge until death, or censoring. A patient was classified as
discontinued if they had no further prescription within the duration of a prescrip-
tion plus a grace period of 90 days. RESULTS: Of the 7,888 linked patients with at
least 3 months of follow-up, 865 had a discharge diagnosis of UA, 4108 NSTEMI and
2915 STEMI. Overall 412(48%) UA, 2820(69%) NSTEMI and 1830(63%) STEMI patients
were treated with clopidogrel in primary care within 3 months of discharge. The
proportion of UA patients treated remained relatively stable over the study period
(2003:47%, 2009:38%), in contrast prescribing increased in NSTEMI (2003:41%, 2009:
78%) and STEMI patients (2003:24%, 2009:87%). Statin use was high in all three
groups (734(85%) UA, 3609(88%) NSTEMI, 2784(96%) STEMI) and remained so
throughout the study period. The median time until discontinuation of medicine
was 12 months for clopidogrel and24 months for statin across all three ACS types.
Patterns of discontinuation remained constant across all study years.
CONCLUSIONS: The proportion of patients with STEMI and NSTEMI treated with
clopidogrel increased from 2003 to 2009, in line with national guideline recommen-
dations. However there was no evidence that clinicians differentiated length of
therapy by type of ACS.
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OBJECTIVES: The aim of the study was to analyze use of ACE inhibitors in Serbia
compared with Montenegro in year 2009. METHODS: Data about use of ACE inhib-
itors in Serbia and in Montenegro in 2009 taken from Republic Institute for Health
Insurance from Serbia and from Health Service Fund of Montenegero. RESULTS:
Use of ACE inhibitors in Serbia in 2009 was 179,26 DDD/1000 inh/day and in Mon-
tenegro was 83,32 DDD/1000 inh/day. In Serbia 5.977.289,00€has been spent for ACE
inhibitors and in Montenegro 2.488.464,95€ in the same year. In Serbia on the first
place is enalapril with 78,32 DDD/1000 inh/day or 44,43%, on the second place
fosinopril with 20,09 DDD/1000 inh/day or 11,40%, while on the third place is
ramipril with 19,11 DDD/1000 inh/day or 10,84% of total drug utilization in this
subgroup. Amount spent on enalapril was 1.717.416,00€ or 28,73%, on fosinopril
1.116.972,00€ or 18,69%, and on ramipril 470.937,00€ or 7,88% of total finances spent
on this subgroup C09 in year 2009. In Montenegro on the first place are lisinopril
and hydrochlorothiazide with 19,62 DDD/1000 inh/day or 23,55%, on the second
place are fosinopril and hydrochlorothiazide with 12,77 DDD/1000 inh/day or
15,33%, while on the third place is fosinopril with 11,92 DDD/1000 inh/day or 14,31%
of total drug utilization inside this subgroup. Money spent on lisinopril and hydro-
chlorothiazide are 425.547,30€ or 17,10%, on fosinopril and hydrochlorothiazide
762.333,74€ or 30,63%, and on fosinopril 533.307,43€ or 21,43% of total finances
spent on this subgroup C09 in the year 2009. CONCLUSIONS: Comparing the con-
sumption of ACE inhibitors in Serbia and Montenegro in the year 2009, it becomes
clear that the combination of ACE inhibitors with diuretics is most frequently used
in Montenegro, while in Serbia the use of this combination is on the the fifth place
in this group of drugs.
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OBJECTIVES: To characterise patients with atrial fibrillation (AF) in a UK secondary
care centre. METHODS: Eligible patients admitted to Llandough Hospital (Cardiff,
UK) as an emergency with AF (ICD10 code: I48X), and discharged between 1/10/2009
A368 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
